MSK in the News: December 26 – January 5

  • Memorial Sloan-Kettering has received a $90 million donation as a share of an unprecedented $540 million gift from the Ludwig Cancer Research organization, to 6 prestigious academic institutions.  Memorial will use the funds to support research in immuno-oncology – fighting cancer using the immune system.
  • MSKCC’s Dr. Michael Mauro is pleased that the FDA is allowing sale of the leukemia drug, Iclusig, to resume after it had been taken off the market.
  • Dr. Tim Ahles of MSKCC commented on the phenomenon of premature aging in adult survivors of childhood cancers.

MSKCC in the News: December 1 – December 18

  • MSKCC’s Dr. Leonard Saltz was featured in a Minnesota Public Radio News broadcast about the decision by MSKCC to not stock the colon cancer drug – Zaltrap.
  • MSKCC, Fred Hutchinson Cancer Research Center, and the Seattle Children’s Research Institute have teamed up to launch Juno Therapeutics, a new cancer immunotherapy-focused biotech company.
  • Crain’s New York Business reported that MSKCC and Hunter College will move forward with their planned 1.15 million-square-foot medical complex along the FDR Drive between East 73rd and East 74th streets.

MSKCC in the News: November 1 – November 15

  • Dr. David Gultekin, a research physicist at MSKCC, is quoted in a Public News Service article about research that indicates that wearable smartphones could present health risks – especially from cell-phone radiation.
  • MSKCC aims for 90% staff vaccination for flu by December 1.
  • MSKCC’s Dr. Michael Mauro commented in a New York Times article about the recent announcement by the Food and Drug Administration to suspend sales of a leukemia drug, Iclusig.